Vargas ÁJE, Rodríguez GLM, Herrera VLA

Language: Spanish
References: 15
Page: 19-24
PDF size: 170.04 Kb.

ABSTRACT

Adverse drug reactions are an emergency, and the first contact physician must be completely familiar with them, since they can compromise the function and even the life of patients. Stevens Johnson syndrome/toxic epidermal necrolysis is one of the most studied and reported adverse reactions to date, with a large number of drugs being associated with its appearance. An early diagnosis and an adequate management of the same results in the reduction of mortality caused by this pathology.
We present the case of a 74-year-old patient who presented this event after taking cotrimoxazole.

REFERENCES

1. Organización Mundial de la Salud. Formulario modelo de la OMS 2004: Consejo general a los prescriptores: Efectos adversos e interacciones. Apps.who.int. 2004. Disponible en: https://bit.ly/3Dx3iD2 [Consultado el 13 de noviembre de 2019].

2. Martínez-Cabriales S, Gómez-Flores M, Ocampo-Candiani J. Actualidades en farmacodermias severas: síndrome de Stevens-Johnson (SSJ) y necrólisis epidérmica tóxica (NET). Gaceta Médica de México. 2015;151(6):777-87.

3. Guía de práctica clínica. Diagnóstico y tratamiento del Síndrome de Stevens Johnson/Necrolisis Epidérmica Tóxica, México. Secretaría de Salud; 2011.

4. Auquier-Dunant A, Mockenhaupt M, Naldi L, Correia O, Schroder W, Roujeau JC. Correlations between clinical patterns and causes of erythema Multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol. 2002;138(8):1019-24.

5. Ferreira Roviello C, Menezes Rodrigues F, Bertolini Gonçalves J, Ribeiro Nogueira Ferraz R. Manifestações e tratamento da necrólise epidérmica tóxica e da síndrome de Stevens Johnson. Journal Health NPEPS. 2019;4(1):319-29.

6. Micheletti R, Chiesa-Fuxench Z, Noe M, Stephen S, Aleshin M, Agarwal A et al. Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Multicenter Retrospective Study of 377 Adult Patients from the United States. Journal of Investigative Dermatology. 2018;138(11):2315-21.

7. Harr T, French L. Toxic epidermal necrolysis and Stevens- Johnson syndrome. Orphanet Journal of Rare Diseases. 2010;5(39).

8. Calvo J, Martínez-Martínez L. Mecanismos de acción de los antimicrobianos. Enfermedades Infecciosas y Microbiología Clínica. 2009;27(1):44-52.

9. Charli-Joseph Y, Cruz-Fuentes C, Orozco-Topete R. Incidence of adverse cutaneous drug reactions in a Mexican sample: an exploratory study on their association to tumour necrosis factor alpha TNF2 allele. Journal of the European Academy of Dermatology and Venereology. 2009; 23(7):788-92.

10. Hernández Salazar A, Vega Memije E, Hojyo Tomoka M. Epidemiología de las reacciones cutáneas adversas a fármacos en el Servicio de Dermatología del Hospital General Dr. Manuel Gea González. Revista Mexicana de Dermatología. 2011;55(6):327-33.

11. Hsu D, Brieva J, Silverberg N, Silverberg J. Morbidity and Mortality of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in United States Adults. Journal of Investigative Dermatology. 2016;136(7):1387-97.

12. Carrasquillo O, Santiago‐Vazquez M, Cardona R, Cruz‐ Manzano M, Figueroa L. Stevens‐Johnson syndrome and toxic epidermal necrolysis: a retrospective descriptive study. International Journal of Dermatology. 2019;1-7.

13. Pedigoni Bulisani A, Domingues Sanches G, Penna Guimarães H, Delascio Lopes R, Sandre Vendrame L, Carlos Lopes A. Síndrome de Stevens-Johnson e Necrólise Epidérmica Tóxica em Medicina Intensiva. Revista Brasileira de Terapia Intensiva. 2006;18(3):292-7.

14. Rijal J, Pompa T, Giri S, Bhatt V. A case of toxic epidermal necrolysis caused by trimethoprim-sulfamethoxazole. Case Reports. 2014;2014(jul09 1):bcr2013203163- bcr2013203163.

15. Sassolas B, Haddad C, Mockenhaupt M, et al. ALDEN, an algorithm for assessment of drug causality in Stevens- Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther. 2010;88(1):60-8.